Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

German researchers focus on Na+/H+-exchange inhibitors

Feb. 10, 1997

Chymase inhibitors from Green Cross

Feb. 7, 1997

First Corlopam Renal Program study completed

Feb. 6, 1997

Cell migration inhibitors from Teijin

Feb. 6, 1997

Nortran completes trials in volunteers with antiarrhythmic

Feb. 5, 1997

Tanabe synthesizes ET antagonists

Feb. 5, 1997

AHP claims smooth muscle cell proliferation inhibitors

Feb. 4, 1997

Mylan Laboratories receives FDA approval for generic formulation

Jan. 30, 1997

FDA Cardiovascular and Renal Drugs Advisory Committee to meet February 27-28

Jan. 29, 1997

New use for established antianginal agent

Jan. 29, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...